Evidence mapPaperPMID 41675592Full record

ArticleQuantitative biology (Beijing, China)2026

Protein design and RNA design: Perspectives.

Xi Chen, Xu Dai, Peilong Lu

Abstract read
In one paragraph

Article in Quantitative biology (Beijing, China), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xi ChenResearch Center for Industries of the Future, School of Life Sciences Westlake University Hangzhou Zhejiang China.
Xu DaiResearch Center for Industries of the Future, School of Life Sciences Westlake University Hangzhou Zhejiang China.
Peilong LuResearch Center for Industries of the Future, School of Life Sciences Westlake University Hangzhou Zhejiang China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advances in deep learning and generative modeling have transformed the landscape of protein and RNA design, enabling rapid and precise creation of novel biomolecules with tailored structures and functions. In protein design, generative deep learning frameworks now support backbone generation, sequence optimization, and joint sequence-structure co-design with unprecedented accuracy. These approaches have facilitated broad applications ranging from cyclic peptide and non-natural fold engineering to functional tool development, including small-molecule sensing, catalytic center scaffolding, allosteric switching, intracellular logic circuits, and the targeting of intrinsically disordered proteins. Emerging therapeutic applications-such as immune cell engineering, G protein-coupled receptor-targeted miniproteins, receptor-degrading binders, and thermostable antitoxins-demonstrate the translational potential of computational design. Parallel progress in RNA design, driven by enhanced 3D structure prediction models and generative algorithms, is expanding capabilities in aptamer engineering and RNA-protein complexes, despite ongoing challenges in model generalization and experimental validation. Together, these developments highlight a new era of AI-driven molecular engineering, in which unified protein-RNA modeling, large-scale sampling, and automated experimental pipelines will accelerate the creation of programmable biological systems and next-generation therapeutics.

Indexed as

deep learninggenerative modelsprotein designRNA designsynthetic biology

Identifiers

PMID41675592
PMCPMC12798782

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.